title: Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.
abstract: Tamoxifen has been shown to greatly reduce risk of recurrence and contralateral breast cancer (CBC). Still, second primary contralateral breast cancer is the most common malignancy to follow a first primary breast cancer. Genetic variants in CYP2D6 and other drug-metabolizing enzymes that alter the metabolism of tamoxifen may be associated with CBC risk in women who receive the drug. This is the first study to investigate the impact of this variation on risk of CBC in women who receive tamoxifen. From the population-based Women's Environment Cancer and Radiation Epidemiology (WECARE) Study, we included 624 Caucasian women with CBC (cases) and 1,199 women with unilateral breast cancer (controls) with complete information on tumor characteristics and treatment. Conditional logistic regression was used to assess the risk of CBC associated with 112 single nucleotide polymorphisms (SNPs) in 8 genes involved in the metabolism of tamoxifen among tamoxifen users and non-users. After adjustment for multiple testing, no significant association was observed between any of the genotyped variants and CBC risk in either tamoxifen users or non-users. These results suggest that when using a tagSNP approach, common variants in selected genes involved in the metabolism of tamoxifen are not associated with risk of CBC among women treated with the drug.
authors.affiliation: Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center USA.
authors.forename: Jennifer D
authors.initials: JD
authors.lastname: Brooks
authors.forename: Sharon N
authors.initials: SN
authors.lastname: Teraoka
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Malone
authors.forename: Robert W
authors.initials: RW
authors.lastname: Haile
authors.forename: Leslie
authors.initials: L
authors.lastname: Bernstein
authors.forename: Charles F
authors.initials: CF
authors.lastname: Lynch
authors.forename: Lene
authors.initials: L
authors.lastname: Mellemkjær
authors.forename: David J
authors.initials: DJ
authors.lastname: Duggan
authors.forename: Anne S
authors.initials: AS
authors.lastname: Reiner
authors.forename: Patrick
authors.initials: P
authors.lastname: Concannon
authors.forename: Katherine
authors.initials: K
authors.lastname: Schiermeyer
authors.forename: Juan Pablo
authors.initials: JP
authors.lastname: Lewinger
authors.forename: Jonine L
authors.initials: JL
authors.lastname: Bernstein
authors.forename: Jane C
authors.initials: JC
authors.lastname: Figueiredo
keywords: Contralateral breast cancer; single nucleotide polymorphisms; tamoxifen
references.citation: Clin Pharmacol Ther. 2011 May;89(5):708-17
references.pmid: 21451508
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3837-45
references.pmid: 17761971
references.citation: JAMA. 2009 Oct 7;302(13):1429-36
references.pmid: 19809024
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5187-93
references.pmid: 18024866
references.citation: Breast Cancer Res Treat. 2011 Jan;125(1):279-87
references.pmid: 20809362
references.citation: J Natl Cancer Inst. 2001 May 2;93(9):662-4
references.pmid: 11333277
references.citation: Drug Metab Pharmacokinet. 2012;27(1):122-31
references.pmid: 22041137
references.citation: Breast Cancer Res Treat. 2006 Jan;95(1):13-6
references.pmid: 16317586
references.citation: J Natl Cancer Inst. 2002 Nov 6;94(21):1635-40
references.pmid: 12419790
references.citation: Ann Oncol. 2008 Jan;19(1):56-61
references.pmid: 17947222
references.citation: Curr Med Res Opin. 2010 Nov;26(11):2535-42
references.pmid: 20849243
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9312-8
references.pmid: 16361630
references.citation: Cancer Lett. 2005 Jan 10;217(1):61-72
references.pmid: 15596297
references.citation: J Natl Cancer Inst. 2012 Mar 21;104(6):441-51
references.pmid: 22395644
references.citation: J Clin Oncol. 2010 Jul 20;28(21):3411-5
references.pmid: 20547990
references.citation: Breast Cancer Res. 2005;7(3):R284-90
references.pmid: 15987423
references.citation: Breast Cancer Res Treat. 2005 Jun;91(3):249-58
references.pmid: 15952058
references.citation: Breast Cancer Res. 2004;6(3):R199-214
references.pmid: 15084244
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5010-3
references.pmid: 16951214
references.citation: Steroids. 2007 Nov;72(13):829-42
references.pmid: 17765940
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3708-9; author reply 3709
references.pmid: 16877740
references.citation: Breast Cancer Res Treat. 2012 Jan;131(2):571-80
references.pmid: 21892703
references.citation: Biochem Biophys Res Commun. 1997 Oct 9;239(1):298-304
references.pmid: 9345314
references.citation: Breast Cancer Res. 2010;12(4):R64
references.pmid: 20731819
references.citation: J Natl Cancer Inst. 1995 Sep 20;87(18):1359-64
references.pmid: 7658496
references.citation: Pharmacogenetics. 1997 Aug;7(4):317-25
references.pmid: 9295060
references.citation: Pharmacogenetics. 2002 Apr;12(3):251-63
references.pmid: 11927841
references.citation: Cancer Chemother Pharmacol. 2005 May;55(5):471-8
references.pmid: 15685451
references.citation: Breast. 2011 Apr;20(2):111-8
references.pmid: 21185724
references.citation: Pharmacol Ther. 1984;25(2):127-205
references.pmid: 6438654
references.citation: J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8
references.pmid: 22851268
references.citation: Hum Mutat. 2012 Jan;33(1):158-64
references.pmid: 21898661
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1937-43
references.pmid: 21750172
references.citation: Breast Cancer Res Treat. 2009 Nov;118(1):125-30
references.pmid: 19189212
references.citation: Expert Rev Clin Pharmacol. 2011 May;4(3):363-77
references.pmid: 21709817
references.citation: J Natl Cancer Inst. 2001 Jul 4;93(13):1008-13
references.pmid: 11438566
references.citation: J Natl Cancer Inst. 1995 May 3;87(9):645-51
references.pmid: 7752269
references.citation: Nat Genet. 2001 Apr;27(4):383-91
references.pmid: 11279519
references.citation: J Natl Cancer Inst. 2012 Mar 21;104(6):452-60
references.pmid: 22395643
references.citation: J Natl Cancer Inst. 2008 Jan 2;100(1):32-40
references.pmid: 18159070
references.citation: J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64
references.pmid: 14652237
references.citation: Clin Chem. 2009 Oct;55(10):1770-82
references.pmid: 19574470
references.citation: Int J Epidemiol. 1998 Oct;27(5):743-50
references.pmid: 9839728
references.citation: Pharmacogenetics. 2000 Dec;10(9):789-97
references.pmid: 11191883
references.citation: Am J Hum Genet. 2007 Sep;81(3):559-75
references.pmid: 17701901
references.citation: Lancet. 1998 May 16;351(9114):1451-67
references.pmid: 9605801
references.citation: Breast Cancer Res Treat. 2007 Jan;101(1):113-21
references.pmid: 17115111
references.citation: J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8
references.pmid: 22851270
references.citation: Nat Genet. 2006 Aug;38(8):904-9
references.pmid: 16862161
references.citation: BMC Cancer. 2010 Jun 21;10:313
references.pmid: 20565970
references.citation: Clin Pharmacokinet. 2002;41(12):913-58
references.pmid: 12222994
references.citation: J Natl Cancer Inst. 2012 Aug 22;104(16):1265-6; author reply 1266-8
references.pmid: 22851267
references.citation: Lancet. 2011 Aug 27;378(9793):771-84
references.pmid: 21802721
references.citation: J Natl Cancer Inst. 2011 Mar 16;103(6):489-500
references.pmid: 21325141
references.citation: Breast Cancer Res. 2007;9(1):R7
references.pmid: 17244352